James N. Kochenderfer, MD
James N. Kochenderfer, MD, Investigator in the Surgery Branch of the National Cancer Institute has been named a Top Ten Clinical Research Achievement Awardee by the Clinical Research Forum. Dr. Kochenderfer received the award for his research into the development of chimeric antigen receptor (CAR) T-cell therapy for myeloma, which he and colleagues published in The New England Journal of Medicine.1
Dr. Kochenderfer is a physician-scientist working to develop immunotherapies for lymphoma, leukemia, and multiple myeloma. His current work focuses on CAR T-cell therapies and includes laboratory studies of CAR T-cell biology and clinical studies of CAR T-cell therapies for multiple myeloma and B-cell malignancies after allogeneic hematopoietic stem cell transplantation.
The Clinical Research Forum selected winners of these awards based on the degree of innovation and novelty involved in the advancement of science; contribution to the understanding of human disease and/or physiology; and potential impact upon the diagnosis, prevention, and/or treatment of disease.
The award-winning studies exemplify major advances resulting from the nation’s investment in research to benefit the health and welfare of its citizens and reflect the influential work being conducted by investigators at research institutions and hospitals across the United States and partner institutions from around the world.
The Clinical Research Forum was established in 1996 to provide a forum for discussions of the unique and complex challenges to clinical research among the senior clinical research leadership of leading academic health and science systems. The Clinical Research Forum’s Top Ten Clinical Research Achievement Awards honor outstanding accomplishments in clinical research. Winners are recognized at the Clinical Research Forum Annual Meeting in Washington, DC.
For a complete list of awardees, visit ClinicalResearchForum.org.
1. Raje N, Berdeja J, Kochenderfer JN, et al: Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med 380:1726-1737, 2020.